Progyny, Inc. (PGNY) Free cash flow
- Free cash flow · 12 months (USD): Value $178.38M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 13.61%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $178.38M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $201.25M − $22.86M ≈ $178.38M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 13.61% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $178.38M ÷ $1.31B × 100 ≈ 13.61% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $201.25M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 2.56× | Operating cash flow / net income. Period ending 2026-06-30. $201.25M ÷ $78.63M ≈ 2.56× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 201.25M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 22.86M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 178.38M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.31B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 78.63M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $178.38M | (m) | $201.25M | $22.86M | (m) | $1.31B | (m) | $78.63M | (m) | (m) | 13.61% | 2.56× |
| 2026-03-31 | $184.42M | (m) | $206.33M | $21.91M | (m) | $1.29B | (m) | $67.69M | (m) | (m) | 14.26% | 3.05× |
| 2025-12-31 | $191.78M | (m) | $210.19M | $18.41M | (m) | $1.29B | (m) | $58.52M | (m) | (m) | 14.88% | 3.59× |
| 2025-09-30 | $193.46M | (m) | $208.15M | $14.69M | (m) | $1.27B | (m) | $56.57M | (m) | (m) | 15.25% | 3.68× |
| 2025-06-30 | $190.20M | (m) | $202.00M | $11.80M | (m) | $1.24B | (m) | $53.12M | (m) | (m) | 15.31% | 3.80× |
| 2025-03-31 | $195.78M | (m) | $203.18M | $7.40M | (m) | $1.21B | (m) | $52.50M | (m) | (m) | 16.14% | 3.87× |
| 2024-12-31 | $173.70M | (m) | $179.10M | $5.41M | (m) | $1.17B | (m) | $54.34M | (m) | (m) | 14.88% | 3.30× |
| 2024-09-30 | $160.41M | (m) | $164.60M | $4.19M | (m) | (m) | (m) | $57.27M | (m) | (m) | (m) | 2.87× |
| 2024-06-30 | $170.92M | (m) | $174.27M | $3.35M | (m) | (m) | (m) | $62.75M | (m) | (m) | (m) | 2.78× |
| 2024-03-31 | $190.34M | (m) | $193.59M | $3.24M | (m) | (m) | (m) | $61.26M | (m) | (m) | (m) | 3.16× |
| 2023-12-31 | $185.17M | (m) | $188.81M | $3.64M | (m) | $1.09B | (m) | $62.04M | (m) | (m) | 17.01% | 3.04× |
| 2023-09-30 | $198.99M | (m) | $202.67M | $3.68M | (m) | (m) | (m) | $51.98M | (m) | (m) | (m) | 3.90× |
| 2023-06-30 | $165.41M | (m) | $169.38M | $3.97M | (m) | (m) | (m) | $49.29M | (m) | (m) | (m) | 3.44× |
| 2023-03-31 | $108.92M | (m) | $112.62M | $3.70M | (m) | (m) | (m) | $43.06M | (m) | (m) | (m) | 2.62× |
| 2022-12-31 | $77.15M | (m) | $80.39M | $3.24M | (m) | $786.91M | (m) | $30.36M | (m) | (m) | 9.80% | 2.65× |
| 2022-09-30 | $34.56M | (m) | $37.69M | $3.13M | (m) | (m) | (m) | $42.03M | (m) | (m) | (m) | 0.90× |
| 2022-06-30 | $38.35M | (m) | $40.96M | $2.61M | (m) | (m) | (m) | $45.62M | (m) | (m) | (m) | 0.90× |
| 2022-03-31 | $11.69M | (m) | $14.24M | $2.55M | (m) | (m) | (m) | $55.57M | (m) | (m) | (m) | 0.26× |
| 2021-12-31 | $23.91M | (m) | $26.04M | $2.13M | (m) | (m) | (m) | $65.77M | (m) | (m) | (m) | 0.40× |
| 2021-09-30 | $22.14M | (m) | $23.76M | $1.61M | (m) | (m) | (m) | $89.76M | (m) | (m) | (m) | 0.26× |
| 2021-06-30 | $13.88M | (m) | $14.93M | $1.04M | (m) | (m) | (m) | $77.79M | (m) | (m) | (m) | 0.19× |
| 2021-03-31 | $23.88M | (m) | $24.59M | $713.00K | (m) | (m) | (m) | $58.00M | (m) | (m) | (m) | 0.42× |
| 2020-12-31 | $35.17M | (m) | $36.20M | $1.04M | (m) | (m) | (m) | $46.46M | (m) | (m) | (m) | 0.78× |
| 2020-09-30 | $20.96M | (m) | $24.18M | $3.22M | (m) | (m) | (m) | $3.20M | (m) | (m) | (m) | 7.56× |
| 2020-06-30 | $11.24M | (m) | $14.73M | $3.49M | (m) | (m) | (m) | $-10.37M | (m) | (m) | (m) | -1.42× |
| 2020-03-31 | $13.25M | (m) | $16.78M | $3.52M | (m) | (m) | (m) | $-7.03M | (m) | (m) | (m) | -2.39× |
| 2019-12-31 | $-4.49M | (m) | $-1.53M | $2.96M | (m) | (m) | (m) | $-8.57M | (m) | (m) | (m) | 0.18× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.38M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-971.00K | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.69M | (m) | $2.27M | $579.00K | (m) | (m) | (m) | $661.00K | (m) | (m) | (m) | 3.44× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-10.09M | (m) | $-9.47M | $612.00K | (m) | (m) | (m) | $-12.45M | (m) | (m) | (m) | 0.76× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |